Pharma companies set for strong performance in March 2025 quarter amid earning (...)
Sun Pharma is expected to post a 9% year-on-year revenue growth, supported by its US specialty portfolio and steady growth in chronic therapies in India.
Site référencé: The Economic Times
The Economic Times
RailTel shares rally 10% after Q4 profit jumps 46% YoY
2/05/2025
Vedanta shares in focus after 154% YoY jump in Q4 PAT
2/05/2025
Paras Defence shares in focus after Q4 profit surges 97% YoY ; board approves stock split
2/05/2025
ETMarkets Smart Talk : Gold is more than a safe haven now - Pradeep Gupta on the rise of a new asset class leader
2/05/2025
While we should avoid errors of non-regulation, over-regulation is not the answer, says Sebi chief Tuhin Kanta Pandey
2/05/2025
China 'evaluating' US offer to negotiate tariffs ; Beijing's door is 'open'
2/05/2025
